Financial & Business News
LATEST INVESTING HEADLINES
NEW YORK CITY, NY / ACCESS Newswire / April 18, 2025 / WHY: New York, N.Y., April 18, 2025.
PORTLAND, Ore. , April 18, 2025 /PRNewswire/ -- On April 18, 2025, the board of directors of Portland General Electric Company (NYSE: POR) declared a quarterly common stock dividend of $0.525 per share, representing an increase of 5%, or $0.10 per share, on an annualized basis.
Good news from the laboratory and a clutch of bullish analyst notes were the drivers behind Verve Therapeautics' (VERV 2.00%) big stock price leap this week. By the time the dust cleared, the biotech company's shares soared 40% higher over the period, according to data compiled by S&P Global Market Intelligence.
NEW YORK, NY / ACCESS Newswire / April 18, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=143979&wire=1 or contact Joseph E. Levi, Esq.
SAN DIEGO , April 18, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons or entities that purchased or otherwise acquired Ibotta, Inc. (NYSE: IBTA) common stock pursuant and/or traceable to the registration statement and related prospectus issued in connection with Ibotta's April 18, 2024 initial public offering. Ibotta purports to be a technology company that allows consumer packaged goods brands to deliver digital promotions to millions of consumers through its network called the Ibotta Performance Network.
SAN DIEGO , April 18, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Zenas BioPharma purports to be a "clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need.
NEW YORK , April 18, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the "Class Period"), of the important May 19, 2025 lead plaintiff deadline. So What: If you purchased Zynex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, NY / ACCESS Newswire / April 18, 2025 / If you suffered a loss on your Quantum Computing Inc. (NASDAQ:QUBT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/quantum-computing-inc-lawsuit-submission-form?prid=143975&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / April 18, 2025 / If you suffered a loss on your Skyworks Solutions, Inc. (NASDAQ:SWKS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/skyworks-solutions-inc-lawsuit-submission-form?prid=143978&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / April 18, 2025 / If you suffered a loss on your AppLovin Corporation (NASDAQ:APP) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applovin-corporation-lawsuit-submission-form?prid=143977&wire=1 or contact Joseph E. Levi, Esq.